Health Care [ 5/12 ] | Biotechnology [ 25/74 ]
NASDAQ | Common Stock
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function.
The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis.
It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway.
The company has license agreement with Yale University for specified therapeutic and prophylactic products.
Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 10, 25 | -0.42 Decreased by -27.27% | -0.37 Decreased by -12.51% |
| Nov 5, 24 | -0.39 Decreased by -34.48% | -0.44 Increased by +11.36% |
| Aug 6, 24 | -0.44 Decreased by -25.71% | -0.39 Decreased by -12.82% |
| May 7, 24 | -0.38 Increased by +5.00% | -0.36 Decreased by -5.56% |
| Mar 12, 24 | -0.33 Increased by +21.43% | -0.32 Decreased by -3.13% |
| Nov 7, 23 | -0.29 Increased by +23.68% | -0.32 Increased by +9.38% |
| Aug 8, 23 | -0.35 Increased by +7.89% | -0.43 Increased by +18.60% |
| May 9, 23 | -0.40 Increased by +43.66% | -0.45 Increased by +11.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by -100.00% | -27.07 M Decreased by -25.67% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -24.57 M Decreased by -47.67% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -27.03 M Decreased by -73.48% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -23.35 M Decreased by -43.83% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 1.98 M Increased by +N/A% | -21.54 M Decreased by -16.18% | Decreased by -1.09 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -16.64 M Decreased by -5.09% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -15.58 M Decreased by -4.30% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -16.23 M Increased by +4.12% | Decreased by N/A% Decreased by N/A% |